X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs CADILA HEALTHCARE - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. CADILA HEALTHCARE WOCKHARDT LTD./
CADILA HEALTHCARE
 
P/E (TTM) x -18.4 18.2 - View Chart
P/BV x 2.0 4.1 47.3% View Chart
Dividend Yield % 0.0 1.0 0.2%  

Financials

 WOCKHARDT LTD.   CADILA HEALTHCARE
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
CADILA HEALTHCARE
Mar-18
WOCKHARDT LTD./
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,012558 181.4%   
Low Rs532362 147.0%   
Sales per share (Unadj.) Rs355.9116.3 306.0%  
Earnings per share (Unadj.) Rs-60.317.9 -337.4%  
Cash flow per share (Unadj.) Rs-46.823.1 -202.2%  
Dividends per share (Unadj.) Rs0.013.50 0.3%  
Dividend yield (eoy) %00.8 0.2%  
Book value per share (Unadj.) Rs257.885.4 301.8%  
Shares outstanding (eoy) m110.631,023.74 10.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.24.0 54.9%   
Avg P/E ratio x-12.825.7 -49.8%  
P/CF ratio (eoy) x-16.519.9 -83.0%  
Price / Book Value ratio x3.05.4 55.6%  
Dividend payout %019.6 -0.1%   
Avg Mkt Cap Rs m85,379470,664 18.1%   
No. of employees `0006.311.8 52.9%   
Total wages/salary Rs m9,37118,545 50.5%   
Avg. sales/employee Rs Th6,295.010,072.7 62.5%   
Avg. wages/employee Rs Th1,498.31,569.1 95.5%   
Avg. net profit/employee Rs Th-1,066.31,547.7 -68.9%   
INCOME DATA
Net Sales Rs m39,369119,049 33.1%  
Other income Rs m1,2021,132 106.2%   
Total revenues Rs m40,571120,181 33.8%   
Gross profit Rs m1828,475 0.1%  
Depreciation Rs m1,4955,388 27.8%   
Interest Rs m2,555911 280.5%   
Profit before tax Rs m-2,83023,308 -12.1%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2575,644 4.6%   
Profit after tax Rs m-6,66918,292 -36.5%  
Gross profit margin %023.9 0.2%  
Effective tax rate %-9.124.2 -37.5%   
Net profit margin %-16.915.4 -110.2%  
BALANCE SHEET DATA
Current assets Rs m33,79682,005 41.2%   
Current liabilities Rs m26,91760,720 44.3%   
Net working cap to sales %17.517.9 97.7%  
Current ratio x1.31.4 93.0%  
Inventory Days Days7973 108.5%  
Debtors Days Days8998 90.8%  
Net fixed assets Rs m39,66483,703 47.4%   
Share capital Rs m5531,024 54.0%   
"Free" reserves Rs m27,96886,421 32.4%   
Net worth Rs m28,52287,445 32.6%   
Long term debt Rs m21,73125,551 85.0%   
Total assets Rs m81,620180,653 45.2%  
Interest coverage x-0.126.6 -0.4%   
Debt to equity ratio x0.80.3 260.8%  
Sales to assets ratio x0.50.7 73.2%   
Return on assets %-5.010.6 -47.4%  
Return on equity %-23.420.9 -111.8%  
Return on capital %-7.722.0 -34.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80742,683 23.0%   
Fx outflow Rs m1,78911,242 15.9%   
Net fx Rs m8,01931,441 25.5%   
CASH FLOW
From Operations Rs m6849,193 7.4%  
From Investments Rs m6,302-9,737 -64.7%  
From Financial Activity Rs m-7,695515 -1,494.1%  
Net Cashflow Rs m-664-29 2,289.7%  

Share Holding

Indian Promoters % 74.5 74.8 99.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 8.3 27.7%  
FIIs % 7.7 5.9 130.5%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 11.0 140.0%  
Shareholders   67,757 44,069 153.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   MERCK LTD  CIPLA  TORRENT PHARMA  SUVEN LIFE  WYETH LTD  

Compare WOCKHARDT LTD. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Dec 12, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - FRESENIUS KABI ONCO. COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS